Related Experiment Video
Updated: Oct 17, 2025
09:09
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
6.2K
Eudragit, a Nifty Polymer for Anticancer Preparations: A Patent Review
Priyanka Kriplani1, Kumar Guarve1
1Guru Gobind Singh College of Pharmacy, Yamuna Nagar, 135001, Haryana, India.
Recent Patents on Anti-Cancer Drug Discovery
|October 14, 2021
Summary
Eudragit polymers offer advanced drug delivery for cancer treatment, enhancing bioavailability and reducing side effects. Recent patents highlight their potential in novel therapeutic interventions for various tumors.
Area of Science:
- Pharmaceutical Science
- Polymer Chemistry
- Oncology
Background:
- Polymers are crucial in pharmaceutical formulations for controlled drug release.
- Eudragit polymers, a class of polymethacrylates, are versatile for designing drug delivery systems.
- These polymers offer tunable properties for enhanced bioavailability and site-specific drug delivery.
Purpose of the Study:
- To review recent patents on Eudragit applications in cancer treatment and other ailments.
- To highlight Eudragit's role in advanced drug delivery systems.
Main Methods:
- Patent literature review focusing on Eudragit in cancer drug delivery.
- Analysis of Eudragit's properties and applications in various dosage forms.
Main Results:
- Eudragit excels as a coating polymer and matrix former in drug delivery systems.
- It improves drug bioavailability through site-specific delivery.
- Eudragit can mitigate side effects and toxicity of anticancer drugs.
Conclusions:
- Eudragit demonstrates significant potential for drug delivery in cancer therapy.
- Its application may pave the way for innovative therapeutic strategies against various tumors.
Related Concept Videos
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
18
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
18
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
16
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
16